This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mancilla, E. E. Articles by Baron, J. Search for Related Content PubMed PubMed Citation Articles by Mancilla, E. E. Articles by Baron, J.

Effects of Fibroblast Growth Factor-2 on Longitudinal Bone Growth¹

Developmental Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892

Address all correspondence and requests for reprints to: Jeffrey Baron, Developmental Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Building 10, Room 10N262, 10 Center Drive, MSC 1862, Bethesda, Maryland 20892-1862. E-mail: Jeffrey_Baron{at}nih.gov

In vivo, fibroblast growth factor-2 (FGF-2) inhibits longitudinal bone growth. Similarly, activating FGF receptor 3 mutations impair growth in achondroplasia and thanatophoric dysplasia. To investigate the underlying mechanisms, we chose a fetal rat metatarsal organ culture system that would maintain growth plate histological architecture. Addition of FGF-2 to the serum-free medium inhibited longitudinal growth. We next assessed each major component of longitudinal growth: proliferation, cellular hypertrophy, and cartilage matrix synthesis. Surprisingly, FGF-2 stimulated proliferation, as assessed by [³H]thymidine incorporation. However, autoradiographic studies demonstrated that this increased proliferation occurred only in the perichondrium, whereas decreased labeling was seen in the proliferative and epiphyseal chondrocytes. FGF-2 also caused a marked decrease in the number of hypertrophic chondrocytes. To assess cartilage matrix synthesis, we measured ³⁵SO₄ incorporation into newly synthesized glycosaminoglycans. Low concentrations (10 ng/ml) of FGF-2 stimulated cartilage matrix production, but high concentrations (1000 ng/ml) inhibited matrix production. We conclude that FGF-2 inhibits longitudinal bone growth by three mechanisms: decreased growth plate chondrocyte proliferation, decreased cellular hypertrophy, and, at high concentrations, decreased cartilage matrix production. These effects may explain the impaired growth seen in patients with achondroplasia and related skeletal dysplasias.

This article has been cited by other articles:

				C. J. Xian Roles of Epidermal Growth Factor Family in the Regulation of Postnatal Somatic Growth Endocr. Rev., May 1, 2007; 28(3): 284 - 296. [Abstract] [Full Text] [PDF]

				B. C. J. van der Eerden, M. Karperien, and J. M. Wit Systemic and Local Regulation of the Growth Plate Endocr. Rev., December 1, 2003; 24(6): 782 - 801. [Abstract] [Full Text] [PDF]

				V. Abad, J. L. Meyers, M. Weise, R. I. Gafni, K. M. Barnes, O. Nilsson, J. D. Bacher, and J. Baron The Role of the Resting Zone in Growth Plate Chondrogenesis Endocrinology, May 1, 2002; 143(5): 1851 - 1857. [Abstract] [Full Text] [PDF]

				M. Weise, S. De-Levi, K. M. Barnes, R. I. Gafni, V. Abad, and J. Baron Effects of estrogen on growth plate senescence and epiphyseal fusion PNAS, May 24, 2001; (2001) 121180498. [Abstract] [Full Text] [PDF]

				L. Chen, C. Li, W. Qiao, X. Xu, and C. Deng A Ser365{->}Cys mutation of fibroblast growth factor receptor 3 in mouse downregulates Ihh/PTHrP signals and causes severe achondroplasia Hum. Mol. Genet., March 1, 2001; 10(5): 457 - 465. [Abstract] [Full Text] [PDF]

				F. De Luca, J. A. Uyeda, V. Mericq, E. E. Mancilla, J. A. Yanovski, K. M. Barnes, M. H. Zile, and J. Baron Retinoic Acid Is a Potent Regulator of Growth Plate Chondrogenesis Endocrinology, January 1, 2000; 141(1): 346 - 353. [Abstract] [Full Text] [PDF]

				J. Van Wyk Insulin-Like Growth Factors and Skeletal Growth: Possibilities for Therapeutic Interventions J. Clin. Endocrinol. Metab., December 1, 1999; 84(12): 4349 - 4354. [Full Text]

				M. Sahni, D.-C. Ambrosetti, A. Mansukhani, R. Gertner, D. Levy, and C. Basilico FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway Genes & Dev., June 1, 1999; 13(11): 1361 - 1366. [Abstract] [Full Text]

				Y. Wang, M. K. Spatz, K. Kannan, H. Hayk, A. Avivi, M. Gorivodsky, M. Pines, A. Yayon, P. Lonai, and D. Givol A mouse model for achondroplasia produced by targeting fibroblast growth factor receptor 3 PNAS, April 13, 1999; 96(8): 4455 - 4460. [Abstract] [Full Text] [PDF]

				M. Weise, S. De-Levi, K. M. Barnes, R. I. Gafni, V. Abad, and J. Baron Effects of estrogen on growth plate senescence and epiphyseal fusion PNAS, June 5, 2001; 98(12): 6871 - 6876. [Abstract] [Full Text] [PDF]